Literature DB >> 20299055

Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.

Isaac J Powell1, Cathryn H Bock, Julie J Ruterbusch, Wael Sakr.   

Abstract

PURPOSE: The incidence of prostate cancer is approximately 60% higher and the mortality rate is 2 to 3 times greater in black than in white American men. We propose that a more rapid prostate cancer growth rate and/or earlier transformation from latent to aggressive prostate cancer in black than in white men contribute to this disparity.
MATERIALS AND METHODS: We evaluated entirely embedded prostate glands on autopsy from 1,056 black and white men who died of causes other than prostate cancer. We also reviewed data from our radical prostatectomy database and from the Detroit Surveillance, Epidemiology and End Results database.
RESULTS: Autopsy data indicated that subclinical prostate cancer in black and white men starts at early age and clinical characteristics do not differ by race at early ages. Radical prostatectomy specimen data revealed that prostate cancer volume and Gleason grade were greater in black than in white men. Advanced or metastatic prostate cancer occurred at a 4:1 ratio in black and white men, respectively, in the Detroit Surveillance, Epidemiology and End Results registry database.
CONCLUSIONS: Results showed that age at prostate cancer initiation and clinical characteristics did not differ by race in our autopsy series, prostate cancer volume after radical prostatectomy was greater in black than in white men and disease became distant disease at a ratio of 4 black men to 1 white man in the Detroit Surveillance, Epidemiology and End Results population. These findings support the concept that prostate cancer grows more rapidly in black than in white men and/or earlier transformation from latent to aggressive prostate cancer occurs in black than in white men. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20299055      PMCID: PMC3840791          DOI: 10.1016/j.juro.2010.01.015

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

1.  Racial/ethnic disparities in the treatment of localized/regional prostate cancer.

Authors:  Willie Underwood; Sonya De Monner; Peter Ubel; Angela Fagerlin; Martin G Sanda; John T Wei
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

2.  Effects of race and hypertension on flow-mediated and nitroglycerin-mediated dilation of the brachial artery.

Authors:  N Gokce; M Holbrook; S J Duffy; S Demissie; L A Cupples; E Biegelsen; J F Keaney; J Loscalzo; J A Vita
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

3.  Outcome of African American men screened for prostate cancer: the Detroit Education and Early Detection Study.

Authors:  I J Powell; L Heilbrun; P L Littrup; A Franklin; J Parzuchowski; D Gelfand; W Sakr
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

4.  Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA).

Authors: 
Journal:  Oncology (Williston Park)       Date:  2000-02       Impact factor: 2.990

5.  Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

Authors:  T R Rebbeck; J M Jaffe; A H Walker; A J Wein; S B Malkowicz
Journal:  J Natl Cancer Inst       Date:  1998-08-19       Impact factor: 13.506

6.  Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus.

Authors:  Christiane Robbins; Jada Benn Torres; Stanley Hooker; Carolina Bonilla; Wenndy Hernandez; Angela Candreva; Chiledum Ahaghotu; Rick Kittles; John Carpten
Journal:  Genome Res       Date:  2007-10-31       Impact factor: 9.043

Review 7.  Cancer disparities by race/ethnicity and socioeconomic status.

Authors:  Elizabeth Ward; Ahmedin Jemal; Vilma Cokkinides; Gopal K Singh; Cheryll Cardinez; Asma Ghafoor; Michael Thun
Journal:  CA Cancer J Clin       Date:  2004 Mar-Apr       Impact factor: 508.702

8.  Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort.

Authors:  Xianglin L Du; Shenying Fang; Ann L Coker; Maureen Sanderson; Corrine Aragaki; Janice N Cormier; Yan Xing; Beverly J Gor; Wenyaw Chan
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

9.  Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Authors:  Christopher L Amling; Robert H Riffenburgh; Leon Sun; Judd W Moul; Raymond S Lance; Leo Kusuda; Wade J Sexton; Douglas W Soderdahl; Timothy F Donahue; John P Foley; Andrew K Chung; David G McLeod
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

Review 10.  Obesity, metabolic syndrome, and prostate cancer.

Authors:  Ann W Hsing; Lori C Sakoda; Streamson Chua
Journal:  Am J Clin Nutr       Date:  2007-09       Impact factor: 7.045

View more
  127 in total

1.  Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma.

Authors:  Ian M Thompson; Donna P Ankerst; Catherine M Tangen
Journal:  J Natl Cancer Inst       Date:  2010-08-19       Impact factor: 13.506

Review 2.  Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data.

Authors:  Thomas A Dunn; Helen L Fedor; Angelo M De Marzo; Jun Luo
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

Review 3.  Opposing roles of folate in prostate cancer.

Authors:  Kevin J Rycyna; Dean J Bacich; Denise S O'Keefe
Journal:  Urology       Date:  2013-08-28       Impact factor: 2.649

4.  Race, Age, Gender, and Insurance Status: A Comparative Analysis of Access to and Quality of Gastrointestinal Cancer Care.

Authors:  Omid Salehi; Eduardo A Vega; Christopher Lathan; Daria James; Olga Kozyreva; Sylvia V Alarcon; Onur C Kutlu; Beth Herrick; Claudius Conrad
Journal:  J Gastrointest Surg       Date:  2021-05-23       Impact factor: 3.452

5.  Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urology       Date:  2016-09-22       Impact factor: 2.649

6.  Is prostate cancer different in black men? Answers from 3 natural history models.

Authors:  Alex Tsodikov; Roman Gulati; Tiago M de Carvalho; Eveline A M Heijnsdijk; Rachel A Hunter-Merrill; Angela B Mariotto; Harry J de Koning; Ruth Etzioni
Journal:  Cancer       Date:  2017-04-24       Impact factor: 6.860

7.  miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin.

Authors:  Dibash K Das; Michelle Naidoo; Adeodat Ilboudo; Jong Y Park; Thahmina Ali; Konstantinos Krampis; Brian D Robinson; Joseph R Osborne; Olorunseun O Ogunwobi
Journal:  Exp Cell Res       Date:  2016-09-29       Impact factor: 3.905

8.  Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.

Authors:  Isaac J Powell; Fawn D Vigneau; Cathryn H Bock; Julie Ruterbusch; Lance K Heilbrun
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-06       Impact factor: 4.254

9.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Authors:  Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava
Journal:  Lancet Oncol       Date:  2014-05       Impact factor: 41.316

10.  The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study.

Authors:  Kwang Suk Lee; Kyo Chul Koo; Byung Ha Chung
Journal:  Int Urol Nephrol       Date:  2017-09-13       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.